Neutrophils News and Research

RSS

Preventing neutrophils from producing NETs can accelerate wound healing in diabetic mice

One of the body's tools for fighting off infection in a wound may actually slow down the healing process, according to new research by a team of Harvard University, Boston Children's Hospital, and Penn State University scientists.

19 Jun 2015

Scientists find way to accelerate wound healing in diabetic mice

One of the body's own tools for preventing wound infections may actually interfere with wound healing, according to new research from Boston Children's Hospital. In a study published online in Nature Medicine, scientists from the hospital's Program in Cellular and Molecular Medicine found they could speed up wound healing in diabetic mice by keeping immune cells called neutrophils from producing bacteria-trapping neutrophil extracellular traps (NETs).

15 Jun 2015

Researchers show how a new drug speeds tissue regeneration in animal models

The concept sounds like the stuff of science fiction: take a pill, and suddenly new tissues grow to replace damaged ones. Researchers at Case Western Reserve and UT Southwestern Medical Center this week announced that they have taken significant steps toward turning this once-improbable idea into a vivid reality.

12 Jun 2015

Celtaxsys closes $40M Series D financing and receives $5M CFFT grant to conduct CTX-4430 Phase 2 trial

Celtaxsys, Inc., a clinical stage drug development company focused on developing novel therapies for inflammatory diseases, today announced the successful completion of a $40M Series D financing led by Domain Partners VIII. Additional investors in the financing include Lumira Capital, RMI Partners, Masters Capital Management and the Georgia Research Alliance Venture Fund.

8 Jun 2015

Trabectedin may be better than dacarbazine for treatment of soft tissue sarcoma

Janssen Research & Development, LLC announced data from the Phase 3 multicenter study SAR3007, which demonstrated a significant improvement in progression-free survival with trabectedin (YONDELIS®) compared to dacarbazine in patients with advanced liposarcoma (LPS) or leiomyosarcoma (LMS) previously treated with an anthracycline and at least one additional chemotherapy regimen.

2 Jun 2015

Pharmacyclics's Phase III RESONATE™ trial shows adherence to 420mg dose of IMBRUVICA improves outcomes in CLL patients

Pharmacyclics LLC today highlighted results from a sub-analysis of the Phase III RESONATE™ (PCYC-1112) trial, which found that previously-treated patients with chronic lymphocytic leukemia (CLL) who adhered to the recommended 420 mg dose of IMBRUVICA® (ibrutinib) experienced improved progression-free survival (PFS; the primary endpoint) as assessed by an Independent Review Committee (IRC), compared to patients who took lower doses or missed doses, regardless of high-risk genetic factors.

1 Jun 2015

Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Pharmacyclics LLC today announced interim results from the ongoing Phase Ib/II PCYC-1129 study suggesting that ibrutinib (IMBRUVICA) may be a safe and effective treatment for patients with chronic graft-versus-host-disease (cGVHD) who were either refractory to steroid treatment or were steroid-dependent.

1 Jun 2015

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes in CLL/SLL patients

Today, Pharmacyclics LLC announced the results of the Phase III HELIOS trial (CLL3001), which found that patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who received ibrutinib (IMBRUVICA) in combination with bendamustine and rituximab (BR) experienced an 80% reduction in the risk of progression or death compared to patients receiving placebo in combination with BR.

1 Jun 2015

SARIL-RA-TARGET trial: Sarilumab meets co-primary efficacy endpoints in RA patients

Regeneron Pharmaceuticals, Inc. and Sanofi announced today that a Phase 3 study of sarilumab, an investigational, fully human IL-6 receptor antibody, met its co-primary efficacy endpoints of a greater improvement in signs and symptoms of rheumatoid arthritis (RA) at 24 weeks and physical function at 12 weeks, compared to placebo.

21 May 2015

Alnylam files clinical trial application for alpha-1 liver disease, presents data at DDW

Alnylam Pharmaceuticals, Inc. has announced that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 clinical trial with ALN-AAT, a subcutaneously administered investigational RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of AAT deficiency-associated liver disease (alpha-1 liver disease).

19 May 2015

Differences in mechanical, chemical makeup of e-cigarettes can have adverse effects on human health

Unlike standard cigarettes, the components of electronic cigarettes are not regulated and standardized, thus they vary widely between products.

17 May 2015

Combination therapy provides promising results in patients with advanced non-small cell lung cancer

An early phase study testing an anti-PDL1 agent in combination with standard chemotherapy in the treatment of advanced non-small cell lung cancer has provided promising early results, prompting multiple phase III studies in lung cancer. The findings are being presented at the annual meeting of the American Society of Clinical Oncology.

15 May 2015

Novel approach allows real-time imaging of ongoing immune response

A novel approach that allows real-time imaging of the immune system's response to the presence of tumors—without the need for blood draws or invasive biopsies—offers a potential breakthrough both in diagnostics and in the ability to monitor efficacy of cancer therapies.

21 Apr 2015

Administration of selenide protects heart tissue post cardiac arrest, shows study

Damage to heart muscle from insufficient blood supply during cardiac arrest and reperfusion injury after blood flow is restored can be reduced by nearly 90 percent if selenide, a form of the essential nutrient selenium, is administered intravenously in the wake of the attack, according to a new preclinical study by researchers at Fred Hutchinson Cancer Research Center.

10 Apr 2015

Low doses of imatinib drug can push immune system to combat bacterial infections

Low doses of the anti-cancer drug imatinib can spur the bone marrow to produce more innate immune cells to fight against bacterial infections, Emory researchers have found.

1 Apr 2015

IMDC prognostic model valid in second-line RCC therapy

The International Metastatic Renal Cell Carcinoma Database Consortium prognostic model can be applied to metastatic renal cell carcinoma patients receiving second-line targeted treatment, according to research published in The Lancet Oncology.

25 Mar 2015

Pediatric patients who receive quick antibiotics for fever, neutropenia have reduced PICU needs

A University of Colorado Cancer Center study published in the journal Pediatric Blood & Cancer shows that pediatric cancer patients who receive antibiotics within 60 minutes of reporting fever and showing neutropenia (low neutrophil count), go on to have decreased intensive care consultation rate and lower mortality compared with patients who receive antibiotics outside the 60-minute window.

27 Feb 2015

Palbociclib extends progression-free survival in advanced breast cancer patients

Palbociclib, an investigational oral medication that works by blocking molecules responsible for cancer cell growth, is well tolerated and extends progression-free survival (PFS) in newly diagnosed, advanced breast cancer patients, including those whose disease has stopped responding to traditional endocrine treatments.

21 Feb 2015

New research could help pave way to new cancer therapies

New research from the Hebrew University of Jerusalem shows that the most common form of white blood cells, called neutrophils, contain many different subtypes, of which some fight the development of cancer and others promote its progression. The research could help pave the way to new therapies that fight cancer by increasing anti-tumor neutrophils while limiting pro-tumor neutrophils.

23 Jan 2015

Enzymes linked to diabetes, obesity play major roles in arthritis and leukemia

Enzymes linked to diabetes and obesity appear to play key roles in arthritis and leukemia, potentially opening up new avenues for treating these diverse diseases, according to new research at Washington University School of Medicine in St. Louis.

8 Jan 2015

Neutrophils News and Research

Preventing neutrophils from producing NETs can accelerate wound healing in diabetic mice

Scientists find way to accelerate wound healing in diabetic mice

Researchers show how a new drug speeds tissue regeneration in animal models

Celtaxsys closes $40M Series D financing and receives $5M CFFT grant to conduct CTX-4430 Phase 2 trial

Trabectedin may be better than dacarbazine for treatment of soft tissue sarcoma

Pharmacyclics's Phase III RESONATE™ trial shows adherence to 420mg dose of IMBRUVICA improves outcomes in CLL patients

Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes in CLL/SLL patients

SARIL-RA-TARGET trial: Sarilumab meets co-primary efficacy endpoints in RA patients

Alnylam files clinical trial application for alpha-1 liver disease, presents data at DDW

Differences in mechanical, chemical makeup of e-cigarettes can have adverse effects on human health

Combination therapy provides promising results in patients with advanced non-small cell lung cancer

Novel approach allows real-time imaging of ongoing immune response

Administration of selenide protects heart tissue post cardiac arrest, shows study

Low doses of imatinib drug can push immune system to combat bacterial infections

IMDC prognostic model valid in second-line RCC therapy

Pediatric patients who receive quick antibiotics for fever, neutropenia have reduced PICU needs

Palbociclib extends progression-free survival in advanced breast cancer patients

New research could help pave way to new cancer therapies

Enzymes linked to diabetes, obesity play major roles in arthritis and leukemia

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest Life Science News